Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29738227 | 1.00 | CETP (0.61) | CETPSIGMAR1L3MBTL1RAB9AMEN1 | |
| SCHEMBL5706504 | 0.86 | CETP (0.71) | CETPL3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL2087952 | 0.82 | CETP (0.67) | CETPL3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL6349972 | 0.81 | PDK1 (0.69) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL1542482 | 0.81 | TP53 (0.51) | SIGMAR1L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL397003 | 0.78 | PDK1 (0.67) | CETPL3MBTL1RAB9AKDM4ELMNA | |
| SCHEMBL2301094 | 0.78 | CETP (0.68) | CETPL3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL8243174 | 0.78 | CETP (0.62) | CETPL3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL74521 | 0.78 | ALDH1A1 (0.61) | SIGMAR1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL3535796 | 0.77 | PDK1 (0.68) | CETPL3MBTL1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114890856-B | Method for synthesizing 2,2' -biphenyl-1-carboxylic acid derivative | 华南理工大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-114890856-A | Method for synthesizing 2,2' -biphenyl-1-carboxylic acid derivative | 华南理工大学 | 2022-08-12 | — | — | CN | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20090298745-A1 | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors | PROSIDION LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-7186830-B2 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298745-A1 | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors | PYGL, PYGM, G6PC1 | CETP 728/4885SIGMAR1 3994/4885L3MBTL1 3948/4885 |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PC, GOT2, PDK1 | CETP 96/4885SIGMAR1 4081/4885L3MBTL1 3998/4885 |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | CETP 140/4885SIGMAR1 4002/4885L3MBTL1 3836/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | CETP 140/4885SIGMAR1 4002/4885L3MBTL1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.